Influenza Vaccines Market Report 2026

Influenza Vaccines Market Overview

• Influenza Vaccines market size has reached to $9.04 billion in 2025 • Expected to grow to $13.13 billion in 2030 at a compound annual growth rate (CAGR) of 7.8% • Growth Driver: The Rising Incidences Of Seasonal Influenza Drive Growth In The Influenza Vaccine Market • Market Trend: Clover Biopharmaceuticals Introduces Adimflu-S (QIS) • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Influenza Vaccines Market?

Influenza vaccines refer to flu vaccines designed to provide immunity against influenza viruses. These are quadrivalent vaccines, designed to protect against four different flu viruses, including two influenza A viruses and two influenza B viruses. The main types of influenza vaccines are inactivated and live attenuated vaccines. An inactivated refers to a type of vaccine that contains killed or inactivated microorganisms or viruses to stimulate an immune response without causing disease and is used to prevent infection and reduce the severity of illness caused by influenza viruses. They are available as quadrivalent and trivalent and are administered as injections and nasal sprays for people aged pediatric and adult. These are distributed through hospitals and pharmacies, government and institutional supply, and other distribution channels.

What Is The Influenza Vaccines Market Growth Forecast?

The influenza vaccines market size is expected to see strong growth in the next few years. It will grow to $13.13 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing adoption of quadrivalent vaccines, expansion of precision medicine approaches, growing government vaccination initiatives, development of cell-based and recombinant vaccines, enhanced cold chain and distribution infrastructure. Major trends in the forecast period include seasonal vaccine formulation optimization, expansion of pediatric immunization programs, increase in government-funded flu vaccination campaigns, adoption of novel adjuvants for enhanced immunogenicity, growth in home-based and outpatient vaccine delivery.

Global Influenza Vaccines Market Segmentation

1) By Vaccine Type: Inactivated, Live Attenuated 2) By Valency: Quadrivalent, Trivalent 3) By Route Of Administration: Injection, Nasal Spray 4) By Age Group: Pediatric, Adult 5) By Distribution Channel: Hospitals And Pharmacies, Government And Institutional Supply, Other Distribution Channels Subsegments: 1) By Inactivated: Trivalent Inactivated Vaccines (TIV), Quadrivalent Inactivated Vaccines (QIV) 2) By Live Attenuated: Live Attenuated Influenza Vaccines (LAIV), Quadrivalent Live Attenuated Influenza Vaccines (QLAIV)

What Is The Driver Of The Influenza Vaccines Market?

The rising incidences of seasonal influenza are expected to propel the growth of the influenza vaccine market going forward. Seasonal influenza refers to a respiratory illness caused by influenza viruses that typically circulate and cause infections during specific times of the year, usually in the colder months. This shift has resulted from antigenic drift, population susceptibility, environmental factors, incomplete vaccine coverage, and lack of universal vaccination. Influenza vaccines help in reducing the incidences of seasonal influenza by providing immunization against the circulating strains of the virus. For example, in November 2023, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported that during the 2022-2023 flu season, there were approximately 31 million flu-related illnesses, 14 million flu-related medical visits, 360,000 flu-related hospitalizations, and 21,000 flu-related deaths. Therefore, the rising incidences of seasons of influenza are driving the growth of the influenza vaccines industry.

Key Players In The Global Influenza Vaccines Market

Major companies operating in the influenza vaccines market are Pfizer Inc., Merck & Co Inc., Sanofi-Aventis LLC, GlaxoSmithKline plc, Serum Institute of India Private Limited, Seqirus Inc., CSL Limited, Daiichi Sankyo Company Limited, Moderna Inc., Novavax AB, Bharat Biotech International Limited, Valneva SE, Shionogi & Co Ltd., Sinovac Biotech Co Ltd., Walvax Biotechnology Co Ltd., Hualan Biological Engineering Inc., China National Pharmaceutical Group Corporation, Green Cross Corporation, Mitsubishi Tanabe Pharma Corporation, Osivax, Vaxess Technologies Inc., Gamma Vaccines Pty Ltd

Global Influenza Vaccines Market Trends and Insights

Major companies operating in the influenza vaccine market are adopting advanced product innovations, such as quadrivalent seasonal influenza vaccines, to strengthen the company's respiratory vaccine franchise and financial profile. A quadrivalent seasonal influenza vaccine is designed to protect against four different flu viruses, including two influenza A viruses and two influenza B viruses. For instance, in September 2023, Clover Biopharmaceuticals Ltd., a China-based biotechnology company, launched AdimFlu-S (QIS), a quadrivalent seasonal influenza vaccine. This vaccine is the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China. The quadrivalent make-up of the vaccine improves its ability to achieve high vaccine effectiveness, regardless of which influenza B strain becomes seasonally prevalent, when compared to trivalent options.

What Are Latest Mergers And Acquisitions In The Influenza Vaccines Market?

In February 2023, Clover Biopharmaceuticals, a China-based biotechnology company specializing in vaccine research, development, manufacturing, and commercialization, partnered with Adimmune Corporation to exclusively commercialize AdimFlu-S (QIS), a quadrivalent seasonal influenza vaccine, in mainland China. With this partnership, Clover aims to expand its respiratory vaccine franchise by leveraging its established commercial infrastructure to distribute a high-quality quadrivalent influenza vaccine and address growing demand in the Chinese market. Adimmune Corporation is a Taiwan-based vaccine manufacturer that develops and produces critical vaccines.

Regional Insights

North America was the largest region in the influenza vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Influenza Vaccines Market?

The influenza vaccines market consists of sales of recombinant influenza vaccines, high-dose influenza vaccines, cell-based influenza vaccines, and egg-based influenza vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Influenza Vaccines Market Report 2026?

The influenza vaccines market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the influenza vaccines industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.